Please assess the completion status of the following clinical trial:

Trial Title: Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum urate ≥8.0 mg/dL and gout by American Rheumatism Association Criteria~* Renal function defined as a serum creatinine level of \< 2.0 mg/dL and creatinine clearance of \> 20 milliliters per minute (mL/min) by Cockroft and Gault formula.~Exclusion Criteria:~* History of xanthinuria~* Intolerance to allopurinol~* Presence of renal calculi,~* Alcohol intake of ≥ 14 drinks/week~* Clinically significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 240 mg QD (Type: EXPERIMENTAL): None
- Allopurinol QD (Type: ACTIVE_COMPARATOR): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).